Download
slide1 n.
Skip this Video
Loading SlideShow in 5 Seconds..
Mohammed Hammoudeh PowerPoint Presentation
Download Presentation
Mohammed Hammoudeh

Mohammed Hammoudeh

163 Vues Download Presentation
Télécharger la présentation

Mohammed Hammoudeh

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Demographic and Clinical Characteristics of Rheumatoid Arthritis patients in some Arab States: Preliminary analysis Mohammed Hammoudeh Division of Rheumatology, Department of Medicine, Hamad Medical Corporation, Doha, Qatar Member of Middle East Rheumatoid Arthritis Consortium (MERAC) Saskia Mandey, Mohammed Hammoudeh, Ziyad Mahfoud, Wessam G. Elhaq, Marjonneke J Mook-Kanamori, Rawan Shayboub, Samar Al Emadi, Humeira Badsha, Imad Uthman, Hussein Halabi, Basel Masri, Layla Kazkaz, Robert M. Plenge, Cindy McKeon,Thurayya Arayssi

  2. Disclaimer As faculty of Weill Cornell Medical College in Qatar we are committed to providing transparency for any and all external relationships prior to giving an academic presentation. Mohammed Hammoudeh M.D.FACP I DO NOT have a financial interest in commercial products or service.

  3. RA in the Middle East • Badsha H et al. Ann Rheum Dis 66, 835 (2007) • Badsha H et al. ClinRheumatol 27, 739-42 (2008) • There are few systemic large studies of RA in the ME • 15 studies, largest 160 patients, single center • RA is more common in females • High proportion of RF positivity • Association with SE • Conflicting results of severity • Delay in initiation of therapy 1,2 • Low use of DMARDS 1,2 Current study: Genetic studies of Rheumatoid Arthritis in some Arab States (GRAAS)

  4. Genetic studies of Rheumatoid Arthritis in some Arab States Goal: • Investigate the genetic basis of RA in the Middle East by collecting at least 2000 RA and 2000 controls from 5 Rheumatology Centers across 5 Arab States.

  5. Genetic studies of Rheumatoid Arthritis in some Arab States Goal: • Genome Wide Association Study (GWAS) that will test for >30 identified risk alleles identified in European and North American populations

  6. Objective of this Presentation -So far 500 patients are recruited (350 RA and 150 Control )

  7. Objective of this Presentation Describe the demographic and clinical characteristics of the first 150 Rheumatoid Arthritis patients from 5 countries in the Middle East recruited to date ( OCTOBER 2012-FEBRUARY 2013).

  8. Inclusion Criteria • Self reported Arab ancestry • Age > 18 • RA diagnosed per the ACR criteria • Ability to provide informed consent

  9. Data Collection • Two sets of data were collected: • Demographic and clinical data • Ancestry data, based on self-reported ancestry • All data entry is web-based and centralized at WCMC-Q

  10. Results

  11. Nationality percentage (%) Gulf Levant North Africa Analysis done on 150 patients in February 2013

  12. Demographics/ Clinical Analysis done on 150 patients in February 2013

  13. Clinical history Analysis done on 150 patients in February 2013

  14. Demographics Analysis done on 150 patients in February 2013

  15. Lifestyle Analysis done on 150 patients in February 2013

  16. Medications % (percentage) 86% of the patients are using Methotrexate; Analysis done on 150 patients in February 2013

  17. Current Users Methotrexate 60% Oral steroids 35% HCQ 22% SSZ 5% Leflunamide 4.5% Etanrcep 11% Infliximab 4% Adalimumab 10% Rituximab 12% Total on Biologics 37%

  18. Conclusions The patient population of this study is relatively young in comparison to mean age (56.2 years) in the other large databases

  19. Conclusions The patient population of this study is relatively young in comparison to mean age (56.2 years) in the other large databases RF positivity and CCP positivity are low .

  20. Conclusions The patient population of this study is relatively young in comparison to mean age (56.2 years) in the other large databases RF positivity and CCP positivity are low 1/3 of patients are illiterate, which may impact compliance and disease outcome

  21. Conclusions The patient population of this study is relatively young in comparison to mean age (56.2 years) in the other large databases RF positivity and CCP positivity are low 1/3 of patients are illiterate, which may impact compliance and disease outcome Compared to the study done by Badsha et al, there is an increase in the use of Methotrexate (36% vs. 86%)

  22. Conclusions The patient population of this study is relatively young in comparison to mean age (56.2 years) in the other large databases RF positivity and CCP positivity are low 1/3 of patients are illiterate, which may impact compliance and disease outcome Compared to the study done by Badsha et al, there is an increase in the use of Methotrexate (36% vs. 86%) 37% of our RA patients are on biologics ( in Europe 10-30% , in USA 40% )

  23. Future Plans Analyze the demographic and clinical data on a regular basis Encourage more centers to join MERAC

  24. Acknowledgements King Faisal Specialist Hospital & Research center, Jeddah, Kingdom of Saudi Arabia Hussein Halabi Jordan Hospital, Amman, Jordan Basel Masri Tishreen Hospital, Damascus, Syria Layla Kazkaz Broad Institute, Cambridge, MA, USA Robert Plenge Weill Cornell Medical College-Qatar Saskia Mandey Ziyad Mahfoud Wessam G. Elhaq Marjonneke Mook-Kanamori Cindy McKeon Rawan Shayboub Thurayya Arayssi Hamad Medical Corporation, Doha, Qatar Mohammed Hammoudeh SamarAl Emadi Al Biraa Arthritis and Bone Clinic, Dubai, UAE Humeirah Badsha American University of Beirut, Lebanon Imad Uthman

  25. THANK YOU